CB1 cannabinoid receptor inhibition: promising approach for heart failure?
Mukhopadhyay
Partha
P
Section on Oxidative Stress Tissue Injury, Laboratory of Physiological Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892-9413, USA.
Mohanraj
Rajesh
R
Bátkai
Sándor
S
Pacher
Pál
P
D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000187:drug effects; D000077285:Rimonabant; D012307:Risk Factors
D063385:Cannabinoid Receptor Modulators; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant